ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting

    Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients

    Branca Souza1, Juliana Valim2, Fernanda Chaer3, Fernanda Guimarães4 and Verônica Lima5, 1Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, 2Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, 3Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, 4Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, 5Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil

    Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…
  • Abstract Number: 1721 • 2016 ACR/ARHP Annual Meeting

    Subclinical Atherosclerosis Evolution during 5 Years of Anti-Tnfalpha Treatment in Psoriatic Arthritis Patients: Preliminary Data

    Augusta Ortolan1, Giovanni Boschetti2, Mariagrazia Lorenzin1, Giulia Cherobin3, Leonardo Punzi3, Massimo Puato2 and Roberta Ramonda3, 1Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy, 2Clinica Medica III, Department of Medicine DIMED, University of Padova, Padova, Italy, 3Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy

    Background/Purpose:  Psoriatic Arthritis (PsA) is associated with increased morbility and mortality and an accelerated atherosclerosis. Influence of anti-TNFalpha treatment (a widely used therapy in PsA)…
  • Abstract Number: 2652 • 2016 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis and Excess Mortality Associated with Treatments: a Systematic Review and Meta-Analysis

    Manon Redondin1, B Combe2, Cécile Gaujoux-Viala3, Jacques Morel4 and Cédric Lukas5, 1CHU Lapeyronie, University of Montpellier, France, 2Immuno-Rhumatologie, CHU Lapeyronie, University of Montpellier, France, 3CHU Nîmes, University of Montpellier, France, 4Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, 5Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France

                                                                                                                                                                            Background/Purpose: Patients with rheumatoid arthritis (RA) have a lower life expectancy than general population. The impact of RA treatments on global mortality is not…
  • Abstract Number: 252 • 2016 ACR/ARHP Annual Meeting

    Cytokine Profiles of Korean Patients with Adult Onset Still’s Disease Treated with Biologic Agents

    Seung Taek Song1, SuMan Kang2, Sung Won Lee3, Seoung Wan Nam2, Hyukhee Kwon2 and Dae-Hyun Yoo4, 1Division of Rheumatology, Department of Internal Medicine, Cheongju St. Mary's Hospital, Cheongju, Korea, The Republic of, 2Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, 3Department of Rheumatology, Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 4Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose:  Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Several studies have reported that pro-inflammatory cytokines including interleukin (IL)-1, IL-6,…
  • Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting

    Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs

    Natalie Boytsov1, George W. Reed2, Leslie R Harrold2,3, Xiang Zhang1, Carol L Gaich1, Cynthia J Larmore1, Ying Shan2, S Rebello4 and Andre B. Araujo1, 1Eli Lilly and Company, Indianapolis, IN, 2Corrona, LLC, Southborough, MA, 3UMass Medical School, Worcester, MA, 4Epidemiology, Corrona, Southborough, MA

      Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…
  • Abstract Number: 1736 • 2016 ACR/ARHP Annual Meeting

    Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study

    Celine Vidal1, Cédric Lukas2, Bernard Combe3, Francis Berenbaum4, Christian Jorgensen5, Jeremie Sellam6 and Jacques Morel7, 1Rheumatology, Hopital Lapeyronie, Montpellier, France, 2Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 3Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 4Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, 5Inserm u844, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, 6Rheumatology, Saint-Antoine Hospital, Paris, France, 7Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France

    Background/Purpose: TNF inhibitors (TNFi) are effective treatment in radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA). Nr-axSpA have lower response rate in case of absence…
  • Abstract Number: 2718 • 2016 ACR/ARHP Annual Meeting

    Plasma Levels of the M2 Macrophage Markers, CD163 and CD206, Changes Reversely and Soluble CD163 Is Associated with Disease Activity in Spondyloarthritis

    Line Dam Heftdal1,2, René Østgård3,4, Malene Hvid3,5, Bent Deleuran2,3,5, Holger Jon Møller5 and Stinne Greisen2,3, 1Department of Biomedicine, Department of Biomedicine, Aarhus University, Aarhus, Denmark, 2Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 3Department of Biomedicine, Aarhus University, Aarhus, Denmark, 4Department of Rheumatology, Regional Hospital Silkeborg, Silkeborg, Denmark, 5Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

    Background/Purpose: Spondyloarthritis (SpA) covers a group of interrelated auto-inflammatory disorders where TNFa is a central mediator of disease. T cells and macrophages are abundant in…
  • Abstract Number: 433 • 2016 ACR/ARHP Annual Meeting

    The Prevalence of Latent Tuberculosis and Hepatitis B Found after Systematic Screening of Patients Starting with Biological Therapy in a Low-Endemic Area

    Marin de Jong1,2, Danielle Roosen1, Andy Peters1, Valerie Verstraeten3, Marieke Pierik1 and A. van Tubergen4, 1Department of Internal Medicine, division of Gastroenterology, Maastricht University Medical Centre, Maastricht, Netherlands, 2NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, Netherlands, 3Department of Dermatology, Maastricht University Medical Centre, Maastricht, Netherlands, 4Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands

    Background/Purpose:  Biologicals are a powerful treatment option for moderate to severe immune-mediated inflammatory diseases (IMID). Since biologicals modulate the immune system, the risk for reactivation…
  • Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting

    Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

    Theodora Bejan-Angoulvant1, David Ternant2, Fadela Daoued3, Frédéric Medina3, Louis Bernard4, Saloua Mammou3, Gilles Paintaud2 and Denis Mulleman5, 1Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, 2Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, 3Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, 4Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, 5Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France

    Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
  • Abstract Number: 2005 • 2016 ACR/ARHP Annual Meeting

    Exploring the Window of Opportunity for Drug-Free Clinical Remission in Patients with Active, Very Early Peripheral Spondyloarthritis

    Philippe Carron1, Gaëlle Varkas2, Heleen Cypers2, Liesbet Van Praet1, Dirk Elewaut2 and Filip van Den Bosch1, 1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 2Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium

    Background/Purpose: To evaluate drug-free sustained clinical remission and clinical relapse after induction therapy with golimumab in patients with active peripheral Spondyloarthritis (pSpA) in a very…
  • Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting

    The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients

    Mark Berman1, Daphna Paran1, Yonatan Wolman1 and Ori Elkayam2, 1Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 2Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
  • Abstract Number: 604 • 2015 ACR/ARHP Annual Meeting

    Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity

    Jose Inciarte-Mundo1, Julio Ramírez1, Virginia Ruiz-Esquide1, M. Victoria Hernández1, Oscar Camacho1, Sonia Cabrera-Villalba1, Andrea Cuervo1, Mariona Pascal2, Jordi Yagüe2, Juan D. Cañete1 and Raimon Sanmarti1, 1Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, 2Immunology Department, Hospital Clinic i Provincial, Barcelona, Spain

    Background/Purpose: An accurate assessment of disease activity is needed in Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients in remission or low disease activity for…
  • Abstract Number: 1331 • 2015 ACR/ARHP Annual Meeting

    Change in MRI in Patients with Spondyloarthritis Treated with Anti-TNF Agents : Systematic Review of the Literature

    Gisèle KHOURY1, BG Combe2 and Cédric Lukas3, 1Rheumatology, Hopital Lapeyronie, Montpellier, France, 2Lapeyronie, Montpellier, France, 3Hopital Lapeyronie, Montpellier, France

    Background/Purpose: The follow-up of axial spondyloarthritis (SpA) remains difficult in clinical practice, mainly based on patient-reported outcomes, whereas objective parameters in disease monitoring are often…
  • Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting

    Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

    Meghna Jani1, William G Dixon2, Lianne Kearsley-Fleet3, Ian N. Bruce4,5, Hector Chinoy6,7, Anne Barton6,8, Mark Lunt9, Kath Watson3, Deborah P.M. Symmons1, Kimme L. Hyrich3 and on behalf of the BSRBR-RA, 1Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, 2Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 4Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 5Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 6Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 7NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 8NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, 9Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom

    Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…
  • Abstract Number: 2867 • 2015 ACR/ARHP Annual Meeting

    Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study

    Vibeke Strand1, M. Elaine Husni2, Zheng-Yi Zhou3, James Signorovitch3, Jenny Griffith4, Yichen Zhong3 and Arijit Ganguli4, 1Stanford University, Palo Alto, CA, 2Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, 3Analysis Group, Inc., Boston, MA, 4AbbVie Inc., North Chicago, IL

    Background/Purpose: Progression of psoriatic arthritis (PsA) can lead to irreversible joint damage and functional impairment. TNF inhibitors (TNFi’s) have been shown to improve signs and…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology